| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/18/2013 | US20130096172 Methods of treating pediatric patients using dexmedetomidine |
| 04/18/2013 | US20130096171 Methods of treating pediatric patients using dexmedetomidine |
| 04/18/2013 | US20130096170 Methods of treating pediatric patients using dexmedetomidine |
| 04/18/2013 | US20130096169 Treatment of cancer with bio and chemotherapy |
| 04/18/2013 | US20130096168 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
| 04/18/2013 | US20130096166 Camalexin as a treatment for prostate cancer |
| 04/18/2013 | US20130096163 Injectable dosage form of flupirtine |
| 04/18/2013 | US20130096162 Dual-acting antihypertensive agents |
| 04/18/2013 | US20130096158 Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Fingolimod |
| 04/18/2013 | US20130096157 Quinoline derivatives and uses of the same |
| 04/18/2013 | US20130096151 Novel combination and use |
| 04/18/2013 | US20130096149 Heteroaryl compounds and compositions as protein kinase inhibitors |
| 04/18/2013 | US20130096144 Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors |
| 04/18/2013 | US20130096143 N-acyl amino acid derivatives for treating skin conditions such as cellulite |
| 04/18/2013 | US20130096142 Methods for healthy aging |
| 04/18/2013 | US20130096140 Human protein tyrosine phosphatase inhibitors and methods of use |
| 04/18/2013 | US20130096139 Compounds Useful as Inhibitors of ATR Kinase |
| 04/18/2013 | US20130096137 Treating Sexual Desire Disorders with Flibanserin |
| 04/18/2013 | US20130096135 Selected Inhibitors of Protein Tyrosine Kinase Activity |
| 04/18/2013 | US20130096132 Azaadamantane derivatives and methods of use |
| 04/18/2013 | US20130096131 Optical correction |
| 04/18/2013 | US20130096128 Pyrazole compounds useful as protein kinase inhibitors |
| 04/18/2013 | US20130096127 Substituted aminopropionic derivatives as neprilysin inhibitors |
| 04/18/2013 | US20130096126 Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same |
| 04/18/2013 | US20130096121 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 04/18/2013 | US20130096120 Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases |
| 04/18/2013 | US20130096116 Treatment of pharmacological-induced hypochlorhydria |
| 04/18/2013 | US20130096113 Heterocyclic compounds and methods of use thereof |
| 04/18/2013 | US20130096111 Methods Involving Aldose Reductase Inhibitors |
| 04/18/2013 | US20130096110 Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction |
| 04/18/2013 | US20130096106 Compounds and methods for the treatment or prevention of flavivirus infections |
| 04/18/2013 | US20130096105 ArylSulfonamide Based Matrix Metalloprotease Inhibitors |
| 04/18/2013 | US20130096100 Di(arylamino)aryl compound |
| 04/18/2013 | US20130096099 Method of treating brain cancer |
| 04/18/2013 | US20130096096 Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| 04/18/2013 | US20130096095 Small-molecule inhibitors of the androgen receptor |
| 04/18/2013 | US20130096093 Compositions and methods of treatment for inflammatory diseases |
| 04/18/2013 | US20130096090 Transition metal complexes of amino acids and related ligands and their use as catalysts, anti-microbials, and anti-cancer agents |
| 04/18/2013 | US20130096087 Infant nutrition for improving fatty acid composition of brain membranes |
| 04/18/2013 | US20130096086 Mitochondria and human immunodefiency virus type 1 |
| 04/18/2013 | US20130096084 Novel heterocyclic compounds as erk inhbitors |
| 04/18/2013 | US20130096083 Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same |
| 04/18/2013 | US20130096082 Hemostatic compositions |
| 04/18/2013 | US20130096080 Sterile alginate-based aqueous composition for medical use and process for the preparation thereof |
| 04/18/2013 | US20130096079 Anti-Viral Pyrimidine Nucleoside Derivatives |
| 04/18/2013 | US20130096076 Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor |
| 04/18/2013 | US20130096075 Composition for prevention, amelioration or treatment of metabolic syndrome |
| 04/18/2013 | US20130096068 Combination therapy with a proteasome inhibitor and a gallium complex |
| 04/18/2013 | US20130096066 Pharmaceutical formulation for reducing pain |
| 04/18/2013 | US20130096063 Hemostatic compositions |
| 04/18/2013 | US20130096056 Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| 04/18/2013 | US20130095569 Pregnancy-associated plasma protein-a2 (papp-a2) polynucleotides |
| 04/18/2013 | US20130095549 Tweak receptor |
| 04/18/2013 | US20130095482 Methods of detecting pregnancy-associated plasma protein-a2 (papp-a2) |
| 04/18/2013 | US20130095193 Compounds useful as inhibitors of atr kinase |
| 04/18/2013 | US20130095190 Oral liquid vitamin and supplement compositions |
| 04/18/2013 | US20130095188 Method of Encapsulating a Material Using Solvent Removal Technique, and Microspheres/Nanospheres/Matrix Made Therefrom Having Sustained Release Properties |
| 04/18/2013 | US20130095187 Composition for nucleic acid delivery using metal nanoparticles and preparing method thereof |
| 04/18/2013 | US20130095184 Metal-Containing Materials for Treatment of Bacterial Conditions |
| 04/18/2013 | US20130095182 Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders |
| 04/18/2013 | US20130095181 Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
| 04/18/2013 | US20130095180 Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration |
| 04/18/2013 | US20130095179 Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy |
| 04/18/2013 | US20130095178 Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| 04/18/2013 | US20130095177 Method of preparing an oral dosage form comprising fingolimod |
| 04/18/2013 | US20130095176 Controlled release drug delivery compostion |
| 04/18/2013 | US20130095174 Compositions and Methods for Transmucosal Delivery of Lofexidine |
| 04/18/2013 | US20130095169 Compositions and Methods for Reduced Scarring and for Treatment of Fibrosis |
| 04/18/2013 | US20130095161 Copolymers of hydrophobic and hydrophilic segments that reduce protein adsorption |
| 04/18/2013 | US20130095160 Resorbable polystatin biomaterials |
| 04/18/2013 | US20130095157 Cosmetic composition containing retinol stabilized by porous polymer beads and nanoemulsion |
| 04/18/2013 | US20130095156 Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents |
| 04/18/2013 | US20130095155 Topical vitamin d and ubiquinol oral supplement compositions |
| 04/18/2013 | US20130095154 Topical vitamin d oral supplement compositions |
| 04/18/2013 | US20130095146 Ciclesonide containing aqueous pharmaceutical composition |
| 04/18/2013 | US20130095144 Pharmaceutical compositions of sirolimus |
| 04/18/2013 | US20130095143 Biomaterial from wharton's jelly umbilical cord |
| 04/18/2013 | US20130095140 Biguanide Compositions and Methods of Treating Metabolic Disorders |
| 04/18/2013 | US20130095126 Use of substituted heterocyclic compounds to control sea lice on fish |
| 04/18/2013 | US20130095125 Palatinose for enhancing dietary supplement and pharmaceutical delivery |
| 04/18/2013 | US20130095117 Therapeutic uses of inhibitors of rtp801 |
| 04/18/2013 | US20130095114 T Cell Regulation |
| 04/18/2013 | US20130095110 Hyaluronic Acid Decomposition-Promoting Factor and Inhibitor Thereof |
| 04/18/2013 | US20130095107 Biomarker specific to brain/nerve or specific to neuronal differentiation |
| 04/18/2013 | US20130095105 Treatment of Ocular Disease |
| 04/18/2013 | US20130095100 Heterocyclic kinase inhibitors |
| 04/18/2013 | US20130095095 Method for treating thrombotic disorders using quercetin-containing compositions |
| 04/18/2013 | US20130095091 Methods of regulating uptake and transcellular transport of leukocytes and therapeutics |
| 04/18/2013 | US20130095089 Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| 04/18/2013 | US20130095087 Absorbable in situ gel-forming system, method of making and use thereof |
| 04/18/2013 | US20130095074 Use of caftaric acid and lactic bacterium in food supplement for regulating skin pigmentation |
| 04/18/2013 | US20130095069 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 04/18/2013 | US20130095068 Agent for treating hcv infection |
| 04/18/2013 | US20130095067 Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| 04/18/2013 | US20130095066 Compounds for the Treatment of Hepatitis C |
| 04/18/2013 | US20130095064 Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| 04/18/2013 | US20130095063 Compounds for the Treatment of Hepatitis C |
| 04/18/2013 | US20130095059 Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model |
| 04/18/2013 | US20130095057 Compounds for the treatment of clostridium difficile-associated disease |
| 04/18/2013 | US20130095053 Regulation of skin pigmentation by neuregulin-1 (nrg-1) |